{"id":72907,"date":"2021-11-25T11:13:01","date_gmt":"2021-11-25T09:13:01","guid":{"rendered":"https:\/\/www.csregypt.com\/?p=72907"},"modified":"2021-11-25T11:15:06","modified_gmt":"2021-11-25T09:15:06","slug":"astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83","status":"publish","type":"post","link":"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/","title":{"rendered":"AstraZeneca develops new vaccine reducing COVID-19 risk symptoms by 83%"},"content":{"rendered":"

AstraZeneca<\/a> developed new vaccine (AZD7442) that proved to be effective in reducing COVID-19 risk symptoms by 83 percent.<\/p>\n

New data from the AZD7442 COVID-19 PROVENT prevention and TACKLE outpatient treatment Phase III trials both showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination.<\/p>\n

In an analysis of the ongoing PROVENT trial evaluating a median six months of participant follow-up, one 300mg IM dose of AZD7442 reduced the risk of developing symptomatic COVID-19 compared to placebo by 83%.<\/p>\n

About 2% of the\u00a0global\u00a0population is considered at increased risk of an inadequate response to a COVID-19 vaccine.1 <\/sup>This includes people with blood cancers or other cancers being treated with chemotherapy, patients on dialysis, those taking medications after an organ transplant or who are taking immuno-suppressive drugs for conditions including multiple sclerosis and rheumatoid arthritis.2-6<\/sup><\/p>\n

The AZD7442 PROVENT trial is the first Phase III trial prospectively designed to evaluate a monoclonal antibody for pre-exposure prophylaxis of symptomatic COVID-19, with targeted inclusion of high-risk and immune compromised participants. More than 75% of PROVENT participants at baseline had co-morbidities that put them at high risk for severe COVID-19 if they were to become infected, including people who are immune compromised and may have a reduced immune response to vaccination.<\/p>\n

There were no cases of severe COVID-19 or COVID-19-related deaths in those treated with AZD7442 at either the primary or six-month analyses. In the placebo arm, there were two additional cases of severe COVID-19 at the six-month assessment, for a total of five cases of severe COVID-19 and two COVID-related deaths.<\/p>\n

An exploratory analysis of the TACKLE outpatient treatment trial, in patients with mild-to-moderate COVID-19, showed that one 600mg IM dose of AZD7442 reduced the risk of developing severe COVID-19 or death (from any cause) by 88% compared to placebo in patients who had been symptomatic for three days or less at the time of treatment.<\/p>\n

A total of 90% of participants enrolled in TACKLE were from populations at high risk of progression to severe COVID-19 if they became infected, including those with co-morbidities.<\/p>\n

In both PROVENT and TACKLE, AZD7442was generally well tolerated. No new safety issues were identified in the six-month analysis of PROVENT.<\/p>\n

Hugh Montgomery, Professor of Intensive Care Medicine at University College London, UK and AZD7442 principal investigator, said: \u201cThese compelling results give me confidence that this long-acting antibody combination can provide my vulnerable patients with the long-lasting protection they urgently need to finally return to their everyday lives. Importantly, six months of protection was maintained despite the surge of the Delta variant among these high-risk participants who may not respond adequately to vaccination.\u201d<\/p>\n

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said \u201cAZD7442 is the only long-acting antibody with Phase III data to demonstrate benefit in both pre-exposure prophylaxis and treatment of COVID-19 with one dose. These new data add to the growing body of evidence supporting AZD7442\u2019s potential to make a significant difference in the prevention and treatment of COVID-19. We are progressing regulatory filings around the world and look forward to providing an important new option against SARS-CoV-2 as quickly as possible.\u201d<\/p>\n

Full results from PROVENT and TACKLE will be submitted for publication in a peer-reviewed medical journal and presented at a forthcoming medical meeting.<\/p>\n

On 5 October 2021, the Company\u00a0announced<\/a> that it had submitted a request to the US Food and Drug Administration for Emergency Use Authorization for AZD7442 for prophylaxis of COVID-19.<\/p>\n

AstraZeneca has agreed to supply the US Government with 700,000 doses of AZD7442 if granted an Emergency Use Authorization by the FDA, and has agreements to supply to other countries.<\/p>\n","protected":false},"excerpt":{"rendered":"

AstraZeneca developed new vaccine (AZD7442) that proved to be effective in reducing COVID-19 risk symptoms by 83 percent. New data from the AZD7442 COVID-19 PROVENT prevention and TACKLE outpatient treatment Phase III trials both showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination. In an analysis of the ongoing […]<\/p>\n","protected":false},"author":410,"featured_media":72908,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6031,984],"tags":[10946,8520,8633],"yoast_head":"\nAstraZeneca develops new vaccine reducing COVID-19 risk symptoms by 83% - Csr Egypt<\/title>\n<meta name=\"description\" content=\"AstraZeneca developed new vaccine (AZD7442) that proved to be effective in reducing COVID-19 risk symptoms by 83 percent.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca develops new vaccine reducing COVID-19 risk symptoms by 83% - Csr Egypt\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca developed new vaccine (AZD7442) that proved to be effective in reducing COVID-19 risk symptoms by 83 percent.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/\" \/>\n<meta property=\"og:site_name\" content=\"Csr Egypt\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/csregypt\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-25T09:13:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-25T09:15:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/csregypt.com\/wp-content\/uploads\/2021\/11\/pic.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"512\" \/>\n\t<meta property=\"og:image:height\" content=\"288\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Marwa Zein\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@egyptcsrforum\" \/>\n<meta name=\"twitter:site\" content=\"@egyptcsrforum\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Marwa Zein\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/\"},\"author\":{\"name\":\"Marwa Zein\",\"@id\":\"https:\/\/csregypt.com\/#\/schema\/person\/5df2c73ec5c5eaada424a85f98cd7bec\"},\"headline\":\"AstraZeneca develops new vaccine reducing COVID-19 risk symptoms by 83%\",\"datePublished\":\"2021-11-25T09:13:01+00:00\",\"dateModified\":\"2021-11-25T09:15:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/\"},\"wordCount\":608,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/csregypt.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/csregypt.com\/wp-content\/uploads\/2021\/11\/pic.jpg\",\"keywords\":[\"AstraZeneca\",\"COVID-19\",\"vaccine\"],\"articleSection\":[\"health\",\"news\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/\",\"url\":\"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/\",\"name\":\"AstraZeneca develops new vaccine reducing COVID-19 risk symptoms by 83% - Csr Egypt\",\"isPartOf\":{\"@id\":\"https:\/\/csregypt.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/csregypt.com\/wp-content\/uploads\/2021\/11\/pic.jpg\",\"datePublished\":\"2021-11-25T09:13:01+00:00\",\"dateModified\":\"2021-11-25T09:15:06+00:00\",\"description\":\"AstraZeneca developed new vaccine (AZD7442) that proved to be effective in reducing COVID-19 risk symptoms by 83 percent.\",\"breadcrumb\":{\"@id\":\"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/#primaryimage\",\"url\":\"https:\/\/csregypt.com\/wp-content\/uploads\/2021\/11\/pic.jpg\",\"contentUrl\":\"https:\/\/csregypt.com\/wp-content\/uploads\/2021\/11\/pic.jpg\",\"width\":512,\"height\":288,\"caption\":\"AstraZeneca develops new vaccine reducing COVID-19 risk by 83%\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/csregypt.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca develops new vaccine reducing COVID-19 risk symptoms by 83%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/csregypt.com\/#website\",\"url\":\"https:\/\/csregypt.com\/\",\"name\":\"\u0633\u064a \u0625\u0633 \u0622\u0631 \u0645\u0635\u0631\",\"description\":\"The first portal for CSR in Egypt and Middle East\",\"publisher\":{\"@id\":\"https:\/\/csregypt.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/csregypt.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/csregypt.com\/#organization\",\"name\":\"CSR\",\"url\":\"https:\/\/csregypt.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/csregypt.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.csregypt.com\/wp-content\/uploads\/2019\/05\/logos-7.png\",\"contentUrl\":\"https:\/\/www.csregypt.com\/wp-content\/uploads\/2019\/05\/logos-7.png\",\"width\":1080,\"height\":1080,\"caption\":\"CSR\"},\"image\":{\"@id\":\"https:\/\/csregypt.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/csregypt\/\",\"https:\/\/x.com\/egyptcsrforum\",\"https:\/\/www.instagram.com\/csr.egypt\/\",\"https:\/\/www.linkedin.com\/in\/csr-egypt-43381ab5\/\",\"https:\/\/www.pinterest.com.au\/csregypt\/\",\"https:\/\/www.youtube.com\/channel\/UCh21PZpnBj2yjj2PeclXz1g\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/csregypt.com\/#\/schema\/person\/5df2c73ec5c5eaada424a85f98cd7bec\",\"name\":\"Marwa Zein\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/csregypt.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/383ed3b7c60ec18a972e284b402d1b29?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/383ed3b7c60ec18a972e284b402d1b29?s=96&d=mm&r=g\",\"caption\":\"Marwa Zein\"},\"sameAs\":[\"http:\/\/marwazein1982@gmail.com\"],\"url\":\"https:\/\/csregypt.com\/en\/author\/marwa-zein\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca develops new vaccine reducing COVID-19 risk symptoms by 83% - Csr Egypt","description":"AstraZeneca developed new vaccine (AZD7442) that proved to be effective in reducing COVID-19 risk symptoms by 83 percent.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca develops new vaccine reducing COVID-19 risk symptoms by 83% - Csr Egypt","og_description":"AstraZeneca developed new vaccine (AZD7442) that proved to be effective in reducing COVID-19 risk symptoms by 83 percent.","og_url":"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/","og_site_name":"Csr Egypt","article_publisher":"https:\/\/www.facebook.com\/csregypt\/","article_published_time":"2021-11-25T09:13:01+00:00","article_modified_time":"2021-11-25T09:15:06+00:00","og_image":[{"width":512,"height":288,"url":"https:\/\/csregypt.com\/wp-content\/uploads\/2021\/11\/pic.jpg","type":"image\/jpeg"}],"author":"Marwa Zein","twitter_card":"summary_large_image","twitter_creator":"@egyptcsrforum","twitter_site":"@egyptcsrforum","twitter_misc":{"Written by":"Marwa Zein","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/#article","isPartOf":{"@id":"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/"},"author":{"name":"Marwa Zein","@id":"https:\/\/csregypt.com\/#\/schema\/person\/5df2c73ec5c5eaada424a85f98cd7bec"},"headline":"AstraZeneca develops new vaccine reducing COVID-19 risk symptoms by 83%","datePublished":"2021-11-25T09:13:01+00:00","dateModified":"2021-11-25T09:15:06+00:00","mainEntityOfPage":{"@id":"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/"},"wordCount":608,"commentCount":0,"publisher":{"@id":"https:\/\/csregypt.com\/#organization"},"image":{"@id":"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/#primaryimage"},"thumbnailUrl":"https:\/\/csregypt.com\/wp-content\/uploads\/2021\/11\/pic.jpg","keywords":["AstraZeneca","COVID-19","vaccine"],"articleSection":["health","news"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/","url":"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/","name":"AstraZeneca develops new vaccine reducing COVID-19 risk symptoms by 83% - Csr Egypt","isPartOf":{"@id":"https:\/\/csregypt.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/#primaryimage"},"image":{"@id":"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/#primaryimage"},"thumbnailUrl":"https:\/\/csregypt.com\/wp-content\/uploads\/2021\/11\/pic.jpg","datePublished":"2021-11-25T09:13:01+00:00","dateModified":"2021-11-25T09:15:06+00:00","description":"AstraZeneca developed new vaccine (AZD7442) that proved to be effective in reducing COVID-19 risk symptoms by 83 percent.","breadcrumb":{"@id":"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/#primaryimage","url":"https:\/\/csregypt.com\/wp-content\/uploads\/2021\/11\/pic.jpg","contentUrl":"https:\/\/csregypt.com\/wp-content\/uploads\/2021\/11\/pic.jpg","width":512,"height":288,"caption":"AstraZeneca develops new vaccine reducing COVID-19 risk by 83%"},{"@type":"BreadcrumbList","@id":"https:\/\/csregypt.com\/en\/astrazeneca-develops-new-vaccine-reducing-covid-19-risk-symptoms-by-83\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/csregypt.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca develops new vaccine reducing COVID-19 risk symptoms by 83%"}]},{"@type":"WebSite","@id":"https:\/\/csregypt.com\/#website","url":"https:\/\/csregypt.com\/","name":"\u0633\u064a \u0625\u0633 \u0622\u0631 \u0645\u0635\u0631","description":"The first portal for CSR in Egypt and Middle East","publisher":{"@id":"https:\/\/csregypt.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/csregypt.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/csregypt.com\/#organization","name":"CSR","url":"https:\/\/csregypt.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/csregypt.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.csregypt.com\/wp-content\/uploads\/2019\/05\/logos-7.png","contentUrl":"https:\/\/www.csregypt.com\/wp-content\/uploads\/2019\/05\/logos-7.png","width":1080,"height":1080,"caption":"CSR"},"image":{"@id":"https:\/\/csregypt.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/csregypt\/","https:\/\/x.com\/egyptcsrforum","https:\/\/www.instagram.com\/csr.egypt\/","https:\/\/www.linkedin.com\/in\/csr-egypt-43381ab5\/","https:\/\/www.pinterest.com.au\/csregypt\/","https:\/\/www.youtube.com\/channel\/UCh21PZpnBj2yjj2PeclXz1g"]},{"@type":"Person","@id":"https:\/\/csregypt.com\/#\/schema\/person\/5df2c73ec5c5eaada424a85f98cd7bec","name":"Marwa Zein","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/csregypt.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/383ed3b7c60ec18a972e284b402d1b29?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/383ed3b7c60ec18a972e284b402d1b29?s=96&d=mm&r=g","caption":"Marwa Zein"},"sameAs":["http:\/\/marwazein1982@gmail.com"],"url":"https:\/\/csregypt.com\/en\/author\/marwa-zein\/"}]}},"jetpack_featured_media_url":"https:\/\/csregypt.com\/wp-content\/uploads\/2021\/11\/pic.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/posts\/72907"}],"collection":[{"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/users\/410"}],"replies":[{"embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/comments?post=72907"}],"version-history":[{"count":3,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/posts\/72907\/revisions"}],"predecessor-version":[{"id":72912,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/posts\/72907\/revisions\/72912"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/media\/72908"}],"wp:attachment":[{"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/media?parent=72907"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/categories?post=72907"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/tags?post=72907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}